--- title: "辉瑞第一季度收入增长，但由于研发支出增加，利润下降" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/285199732.md" description: "辉瑞报告第一季度收入增长 5%，达到 144.5 亿美元，超出华尔街预期。然而，净收入下降至 26.9 亿美元，受到研发费用上涨 12% 的影响。调整后的每股收益为 75 美分，超过分析师预测的 72 美分。公司仍面临 COVID-19 产品销售下滑的挑战，并专注于新药开发，包括收购 Metsera。辉瑞维持全年收入指引在 595 亿美元至 625 亿美元之间，调整后每股收益在 2.80 美元至 3 美元之间" datetime: "2026-05-05T11:45:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285199732.md) - [en](https://longbridge.com/en/news/285199732.md) - [zh-HK](https://longbridge.com/zh-HK/news/285199732.md) --- # 辉瑞第一季度收入增长，但由于研发支出增加，利润下降 By Nicholas G. Miller Pfizer posted higher first-quarter revenue but lower profit that was weighed down partially by higher research and development spending. The company posted net income of $2.69 billion, or 47 cents a share, compared with $2.97 billion, or 52 cents a share, the year prior. Adjusted earnings were 75 cents a share. Analysts polled by FactSet expected 72 cents a share. The company said its research and development expenses rose 12% due to higher spending in certain oncology and obesity product candidates. Cost of sales also increased on the unfavorable impact of foreign exchange and the favorable revision of the company's estimate of accrued royalties in the first quarter of 2025. Revenue rose 5% to $14.45 billion. Wall Street expected $13.84 billion. The gains were driven by growth for its Padcev cancer drug, its Eliquis blood thinner, Oncology biosimilars and its Nurtec migraine treatment and were partially offset by declines in COVID-19 product revenues. Demand for Pfizer's Covid-19 pharmaceuticals has fallen precipitously since the peak of the pandemic and the company has been looking for new drugs to make up for the drop-off in sales. As part of its strategy to beef up its pipeline, Pfizer agreed to acquire weight-loss drug startup Metsera last year in a deal that could be worth more than $10 billion. The company reiterated its full-year guidance for revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3 a share. Analysts see full-year sales of $61.38 billion and adjusted earnings of $2.96 a share. Write to Nicholas G. Miller at nicholas.miller@wsj.com. (END) Dow Jones Newswires May 05, 2026 07:31 ET (11:31 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. ### 相关股票 - [PFE.US](https://longbridge.com/zh-CN/quote/PFE.US.md) - [ARKG.US](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md) - [IBBQ.US](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md) - [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md) - [VHT.US](https://longbridge.com/zh-CN/quote/VHT.US.md) - [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md) - [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md) - [TBXU.US](https://longbridge.com/zh-CN/quote/TBXU.US.md) - [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md) - [LABU.US](https://longbridge.com/zh-CN/quote/LABU.US.md) - [IXJ.US](https://longbridge.com/zh-CN/quote/IXJ.US.md) - [XLV.US](https://longbridge.com/zh-CN/quote/XLV.US.md) - [IHE.US](https://longbridge.com/zh-CN/quote/IHE.US.md) - [FDS.US](https://longbridge.com/zh-CN/quote/FDS.US.md) - [MTSR.US](https://longbridge.com/zh-CN/quote/MTSR.US.md) ## 相关资讯与研究 - [Scholar Rock 将出席杰富瑞全球医疗保健大会，聚焦 SMA 新药 apitegromab 关键审批](https://longbridge.com/zh-CN/news/287069556.md) - [辉瑞在第二阶段取得强劲的积极结果后，推进关键的儿童肺炎球菌疫苗项目 | PFE 股票新闻](https://longbridge.com/zh-CN/news/287035698.md) - [强生重症肌无力治疗新药获国家药监局批准上市](https://longbridge.com/zh-CN/news/287196062.md) - [CAR-T 迎接新时代](https://longbridge.com/zh-CN/news/286999381.md) - [百时美施贵宝向 3 万名员工全面开放 Anthropic 公司 Claude](https://longbridge.com/zh-CN/news/287085684.md)